[The sensitivity of the CA125 immunoradiometric assay for patients with epithelial ovarian cancer and its correlation with complex treatment].
From 1988 to 1993, 141 patients with epithelial ovarian cancer were treated in our hospital. Histologically, tumors were: 69 serous, 16 mucinous, 6 clear cell, 24 endometrioid, and 26 undifferentiated. Serial serum specimens were obtained from 50 patients at least 2 times in posttreatment 1 to 3 months to observe the correlation between CA125 levels and disease progression or regression. The result showed that CA125 levels were elevated (> 33kU/L) in 65/69 of serous, 0/16 of mucinous, 6/6 of clear cell, 19/24 of endometrioid, 10/26 of undifferentiated tumors. The CA125 determinants was associated with the 80% of cases of nonmucinous epithelial ovarian cancer. Moreover, increases or decreases in CA125 levels have been found to correlate well with disease progression or regression in more than 96% of instances. The determination of CA125 levels may aid in monitoring the response to treatment in patients with epithelial ovarian cancer.
Shi
W
W
Cancer Hospital, Shanghai Medical University.
Zhang
Y J
YJ
Jiang
C Y
CY
D002288:Adenocarcinoma, Mucinous / Q000175:diagnosis; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D018269:Carcinoma, Endometrioid / Q000175:diagnosis; D018283:Cystadenocarcinoma, Papillary / Q000175:diagnosis; D018450:Disease Progression; D005260:Female; D006801:Humans; D015592:Immunoradiometric Assay; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000628:therapy; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen